In the more relevant clinical model of NAFLD, HGF and EGF have both been reported to alleviate steatosis, by facilitating release of lipids from hepatocytes to the blood18,19,22,45. The gene discussed is EGF; the disease is metabolic dysfunction-associated steatotic liver disease.